
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is well-positioned for growth, supported by the successful launch and sale of its CE-Marked Nu.Q NETs automated assay, which has seen adoption across over 20 hospitals in 10 countries and multiple clinical indications. The strategic partnerships with industry leaders Werfen and Hologic for human diagnostics licensing are expected to enhance market penetration and facilitate broader access, particularly in the growth market of China. Additionally, the development of the Nu.Q Vet Feline Test promises to create a new recurring revenue stream in veterinary oncology, further expanding VolitionRX’s market reach in both human and animal diagnostics.
Bears say
VolitionRX Ltd faces increased dilution risk, which negatively impacts its valuation and financial outlook. The adjustment in price target from $5.00 to $3.00 reflects concerns over the sustainability of its business model and the potential for further capital raises. These factors contribute to a pessimistic view on the company's stock performance moving forward.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares